ALMS_OUT_1 [2025-04-02 10:57:10 -0400] 3243 Bytes | 943 tokens | Cum: 943 tkns (11.79% of 8k)
==========================================================================

Alright, let’s light it up, because it's 10:57:10 AM on Wed Apr 02, 2025 -0400, and I'm charging into Alumis (ALMS), popping from 7.24 to 8.4177. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Alumis (ALMS)
IPO: 2024-06-28 (9 Months Ago)
Market Cap: $393,909,047
Shares Outstanding: 47,220,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.

Here's the first list of news for Alumis:

C1 - Mar-25-25 10:51AM - Alumis and Kaken sign agreement in Japan to develop ESK-001
C2 - Mar-25-25 10:51AM 02:30AM - Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
C3 - Mar-21-25 07:08AM - Why Alumis Inc. (ALMS) Went Down On Thursday?
C4 - Mar-19-25 04:05PM - Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
C5 - Mar-10-25 08:00AM - Alumis to Present at Leerink's 2025 Global Healthcare Conference
C6 - Mar-08-25 09:00AM - Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
C7 - Mar-04-25 09:01AM - Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
C8 - Mar-04-25 09:01AM 09:01AM - ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Prior AI Reports for ALMS:
1. 2025-04-01 – Score: 45 – Target: 10.6600 – Highs: – / – / –
high-volume-sparks-hope-despite-bleak-financial-indicators
2. 2025-03-26 – Score: 45 – Target: 5.3000 – Highs: 6.0400 / 5.0500 / 6.00
increased-market-interest-amidst-financial-distress-a-closer-look
3. 2025-03-25 – Score: 30 – Target: 6.1900 – Highs: 5.7000 / 6.0400 / 5.05
alumis-inc-faces-downward-market-trend-amid-zero-revenue

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Alumis (ALMS)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ALMS_OUT_3 [2025-04-02 10:57:16 -0400] 1102 Bytes | 285 tokens | Cum: 1230 tkns (15.38% of 8k)
==========================================================================

Showing C1 (chunk 1 of 4): C1:
**Alumis and Kaken sign agreement in Japan to develop ESK-001**
Date: Mar-25-25 10:51AM
Source: (Pharmaceutical Technology)
URL: https://finance.yahoo.com/m/de51cd0d-f6ce-36a0-ab5e-2494803f19fd/alumis-and-kaken-sign.html

Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development, manufacture and commercialisation of the former’s ESK-001 for dermatological indications in Japan.

The agreement includes options to extend the licence to gastrointestinal and rheumatological conditions.

Kaken will pay Alumis $40m in upfront and near-term co-development payments from 2025 to 2026.

Alumis has the potential to earn additional payments of $140m, depending on milestone achievements and field option fees.

The company is also positioned to obtain tiered royalties on the therapy’s net sales in the country.

Kaken will take charge of the clinical deve

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALMS_OUT_5 [2025-04-02 10:57:17 -0400] 918 Bytes | 289 tokens | Cum: 1631 tkns (20.39% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T14:32:43Z - Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On T...
A2 - 2025-04-01T11:56:53Z - Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Am...
A3 - 2025-03-29T12:34:37Z - HC Wainwright Weighs in on Alumis' Q1 Earnings (NASDAQ:ALMS)...
A4 - 2025-03-27T10:44:45Z - Leerink Partnrs Predicts Alumis' Q2 Earnings (NASDAQ:ALMS)...
A5 - 2025-03-27T12:26:48Z - Alumis (NASDAQ:ALMS) Receives "Buy" Rating from HC Wainwright...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ALMS_OUT_7 [2025-04-02 10:57:20 -0400] 1098 Bytes | 295 tokens | Cum: 1928 tkns (24.10% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday - CoreWeave (NASDAQ:CRWV), Alumis (NASDAQ:ALMS)**Date: 2025-04-01Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/04/44587433/progress-software-posts-upbeat-results-joins-microvast-pvh-and-other-big-stocks-moving-higher-on-tuesdayU.S. stocks were lower, with the Dow Jones index falling over 300 points on Tuesday.

Shares of Progress Software Corporation PRGS rose sharply during Tuesday's session after the company reported better-than-expected quarterly financial results.

Progress Software reported quarterly earnings of $1.31 per share which beat the analyst consensus estimate of $1.06 per share. The company reported quarterly sales of $238.01 million which beat the analyst consensus estimate of $235.63 million.

Progress

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALMS_OUT_9 [2025-04-02 10:57:21 -0400] 1096 Bytes | 341 tokens | Cum: 2343 tkns (29.29% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-19T20:05:00Z - Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
B2 - 2025-03-13T17:52:00Z - Metal-Organic Frameworks Market to Reach $949.2 Million by 2029, Growing at 15.6% CAGR
B3 - 2025-03-08T14:00:00Z - Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
B4 - 2025-03-04T14:01:00Z - Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
B5 - 2025-03-04T14:01:00Z - ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
B6 - 2025-02-06T21:15:00Z - Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALMS_OUT_11 [2025-04-02 10:57:24 -0400] 759 Bytes | 196 tokens | Cum: 2541 tkns (31.76% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/03/g44405196/alumis-reports-year-end-2024-financial-results-and-highlights-recent-achievementsAlumis reported strong 2024 results, with progress on its late-stage pipeline of oral TYK2 inhibitors for immune-mediated diseases. The company also announced a merger agreement with ACELYRIN to create a combined company with a differentiated portfolio and increased financial flexibility.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALMS_OUT_13 [2025-04-02 10:57:25 -0400] 1085 Bytes | 285 tokens | Cum: 2892 tkns (36.15% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-19 8-K Item 2.02 Results of Oper and Fin Cond.

On March 19, 2025, Alumis Inc. (the Company) issued a press release announcing, among other things, its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99....

S2 - 2025-03-19 8-K Item 2.02 Results of Oper and Fin Cond.

On March 19, 2025, Alumis Inc. (the Company) issued a press release announcing, among other things, its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99....

S3 - 2025-03-19 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our CONS financial statements and the related note...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALMS_OUT_15 [2025-04-02 10:57:31 -0400] 1003 Bytes | 260 tokens | Cum: 3154 tkns (39.42% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 2.02 Results of Operations and Financial Condition.

On March 19, 2025, Alumis Inc. (the Company) issued a press release announcing, among other things, its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1.

All of the information furnished in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALMS_OUT_17 [2025-04-02 10:57:42 -0400] 4159 Bytes | 1183 tokens | Cum: 4481 tkns (56.01% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+----------------------+-----------------------+-----------------------+
| Volume: 589,893 | Perf Month: 81.48% | Option/Short: No / No | Sales Y/Y TTM: - |
+---------------------+----------------------+-----------------------+-----------------------+
| Avg Volume: 567.38K | Perf Quarter: 10.77% | Short Float: 12.08% | ROE: -198.66% |
+---------------------+----------------------+-----------------------+-----------------------+
| Rel Volume: 4.66 | Index: RUT | Short Ratio: 5.38 | ROI: -101.72% |
+---------------------+----------------------+-----------------------+-----------------------+
| RSI (14): 77.13 | Market Cap: 453.21M | Short Interest: 3.05M | Sales Surprise: - |
+---------------------+----------------------+-----------------------+-----------------------+
| ATR (14): 0.86 | Shs Outstand: 47.22M | Beta: - | EPS Surprise: -24.94% |
+---------------------+----------------------+-----------------------+-----------------------+
| SMA20: 68.24% | Shs Float: 25.25M | Sales Q/Q: - | P/E: - |
+---------------------+----------------------+-----------------------+-----------------------+
| SMA50: 53.69% | Inst Own: 34.73% | Sales past 5Y: 0.00% | Earnings: Mar 19 AMC |
+---------------------+----------------------+-----------------------+-----------------------+
| SMA200: -11.40% | Insider Own: 53.59% | Employees: 168 | |
+---------------------+----------------------+-----------------------+-----------------------+
| Perf Week: 69.31% | Insider Trans: 0.00% | Debt/Eq: 0.12 | |
+---------------------+----------------------+-----------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -294233000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 8.4
Average Volume: 1162295.35
30-Day High: 8.4
30-Day Low: 3.57

[Detailed Financials: TTM 2024]
- Total Assets: $340,992,000.0
- Total Liabilities: $80,888,000.0
- Total Equity: $260,104,000.0
- Current Assets: $306,188,000.0
- Current Liabilities: $50,910,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -10.38

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $123,499,000.0

[Detailed Financials: FY 2024]
- Total Assets: $340,992,000.0
- Total Liabilities: $80,888,000.0
- Total Equity: $260,104,000.0
- Current Assets: $306,188,000.0
- Current Liabilities: $50,910,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -10.38

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $123,499,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ALMS_OUT_19 [2025-04-02 10:57:44 -0400] 676 Bytes | 167 tokens | Cum: 4908 tkns (61.35% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ALMS_IN_21 [2025-04-02 10:57:45 -0400] 126 Bytes | 29 tokens | Cum: 4965 tkns (62.06% of 8k)
==========================================================================

====================================
[2025-04-02 10:57:45] # Analysis Completed
Elapsed Time: 34.94 seconds